

Somatuline[®] Depot (lanreotide) – First-time generic

- On May 23, 2024, Cipla launched an <u>AB-rated</u> generic version of lpsen's <u>Somatuline Depot</u> (<u>lanreotide</u>) 120 mg/0.5 mL injection.
 - Cipla also received FDA approval of generic Somatuline Depot 60 mg/0.2 mL and 90 mg/0.3 mL injections. Launch of these strengths is pending.
- Somatuline Depot is approved for the following indications:
 - Long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option
 - Treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival
 - Treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.